Skip to Content
Merck
All Photos(1)

Key Documents

SML3213

Sigma-Aldrich

Lobaplatin

≥98% (NMR)

Synonym(s):

Cis-[trans-1,2-cyclobutanebis(methylamine)-N,N′]-[(2S)-lactate-O1,O2)-platinum (II), D 19466, D-19466, D19466, [rel-(1R,2R)-1,2-cyclobutanedimethanamine-κN,kN′][(2S)-2-(hydroxy-kO)propanoato(2-)-kO]-, (SP-4-3)-platinum, trans-1,2-Cyclobutanedimethanamine, platinum complex

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C9H18N2O3Pt
CAS Number:
Molecular Weight:
397.33
UNSPSC Code:
12352107
NACRES:
NA.77

Quality Level

Assay

≥98% (NMR)

form

powder

color

white to beige

solubility

H2O: 2 mg/mL, clear (Warmed)

storage temp.

−20°C

SMILES string

O=C1[O-][Pt+2]2(N[CH2]C3CCC3CN2)[O-]C1C

InChI

1S/C6H12N2.C3H5O3.Pt/c7-3-5-1-2-6(5)4-8;1-2(4)3(5)6;/h5-8H,1-4H2;2H,1H3,(H,5,6);/q-2;-1;+4/p-1/t;2-;/m.0./s1

InChI key

HADHSETVEMCBPU-TYOUJGAFSA-M

Biochem/physiol Actions

Lobaplatin (D-19466) is a third-generation platinum anticancer agent in vitro and in vivo, consisting of ~50:50 mixture of the two trans-1,2-cyclobutanedimethanamine diastereomers in complex with L-lactic acid. Llobaplatin shows antitumor efficacy against various human cancer cancer xenografts and significantly prolongs the survival of mice bearing P388 leukemia (mean life span increase post single i.p. in mg/kg = 46%/4.64 & 77/14.7). Compared to first and second generation platinum compounds, lobaplatin appears to be more stable, less toxic, have a better therapeutic index and may overcome tumor resistance.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R Voegeli et al.
Journal of cancer research and clinical oncology, 116(5), 439-442 (1990-01-01)
D-19466, a new platinum complex, was characterized. It showed no nephrotoxic side-effects as determined by the measurement of blood urea. It was cytotoxic in vitro for tumor cells in concentrations comparable to or lower than cytotoxic concentrations of cisplatin. It
A Harstrick et al.
Cancer chemotherapy and pharmacology, 33(1), 43-47 (1993-01-01)
Lobaplatin [1,2-diamminomethylcyclobutane-platinum(II) lactate] is a new platinum compound with interesting preclinical activity and apparently no nephro- or neurotoxicity that is currently undergoing clinical phase II studies. Little is known about the cross-resistance between cisplatin and lobaplatin. The activity of this
Hongming Zhang et al.
Frontiers in oncology, 9, 538-538 (2019-08-21)
Platinum-based chemotherapy is recommended as the first-line treatment regimen for patients with advanced non-small-cell lung cancer (NSCLC). Lobaplatin (LBP), a third-generation platinum anti-neoplastic agent, has shown an improved efficacy. This study is aimed to investigate the mechanisms of LBP-induced apoptosis
Junhui Yu et al.
Cell death & disease, 10(3), 193-193 (2019-02-26)
Pyroptosis, a form of programmed cell death (PCD), has garnered increasing attention as it relates to innate immunity and diseases. However, the involvement of pyroptosis in the mechanism by which lobaplatin acts against colorectal cancer (CRC) is unclear. Our study
Shupei Pan et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 102, 567-574 (2018-03-30)
Radiotherapy is one of the common treatments for esophageal squamous cell carcinoma (ESCC). Yet, local recurrence led by radioresistance is still not solved. Lobaplatin (LBP) is known to have powerful clinical anti-tumor activities in various tumors, but its effect in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service